Multicenter Randomized Controlled Clinical Trial of Indocyanine Green Molecular Fluorescence Imaging in the Diagnosis and Treatment of Primary Liver Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The of this study is to explore the clinical outcomes of indocyanine green molecular fluorescence imaging in local resection of primary hepatocellular carcinoma (CNLC Ⅰa stage).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 66
Healthy Volunteers: f
View:
• First clinical diagnosis of primary liver cancer (China liver cancer staging, CNLC Ia stage);
• Child-Pugh grading standard of liver function was GRADE A or B;
• 18-66 years old;
• Complete clinical case data;
• limited surgical methods (local resection);
• Voluntarily participate in the study and sign the informed consent.
Locations
Other Locations
China
Zhujiang Hospital of Southern Medical University
RECRUITING
Guangzhou
Contact Information
Primary
Chihua Fang, MD
fangchihua@smu.edu.cn
13609700805
Backup
Xiaojun Zeng
zengxiaojun95@126.com
15626104890
Time Frame
Start Date: 2021-09-23
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 348
Treatments
Experimental: ICG molecular fluorescence imaging guided surgery
ICG molecular fluorescence imaging will be used in local hepatectomy of primary liver cancer in this group
Placebo_comparator: No ICG molecular fluorescence imaging guided surgery
ICG molecular fluorescence imaging will not be used in local hepatectomy of primary liver cancer in this group
Related Therapeutic Areas
Sponsors
Leads: Zhujiang Hospital